5 research outputs found
Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-016-0412-8"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides<u></u></p
Cardiovascular drugs<sup>†</sup> prescribed at the end of the visit or at hospital discharge in patients with and without angina.
<p><sup>†</sup>Drugs not reported have been used in less than 5% of cases. ACE-I: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blockers; ASA: acetylsalicylic acid; DAPT: dual antiplatelet therapy; MRA: mineralocorticoid receptor antagonist; OAT: oral anticoagulation therapy.</p
Baseline clinical, hemodynamic and laboratory variables of patients without and with angina.
<p>Baseline clinical, hemodynamic and laboratory variables of patients without and with angina.</p
Timing (days) from diagnostic procedures to enrollment, median (IQR).
<p>Timing (days) from diagnostic procedures to enrollment, median (IQR).</p
Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study - Fig 3
<p>Domain of movement ability (panel A), body care (panel B), daily activities (panel C), pain/worry (panel D), and anxiety/depression (panel E) of the EQ 5D-5L questionnaire in patients with and without angina.</p